Ozempic use in Australian children: what the data actually shows

What did @7newsaustralia actually say?

The segment claims there has been a "surge" in Australian children injecting semaglutide (branded as Ozempic) to manage diabetes, citing new data from the Therapeutic Goods Administration. A doctor interviewed expressed concern that children may be using the drug "to control their weight rather than having a healthy diet," while also acknowledging that type 2 diabetes and obesity often require treating both conditions simultaneously. A second voice noted the data has "divided the medical community."

The framing is worth unpacking. The caption mixes hashtags for "weight" and "weightloss" alongside "diabetes," which subtly conflates two different clinical scenarios. Semaglutide is TGA-approved for type 2 diabetes management, not general pediatric weight loss. The report does not clearly distinguish between these uses, which matters enormously for how viewers interpret the "surge."

Does the science back this up?

The underlying clinical picture is more nuanced than the segment suggests, but the core concern about rising pediatric semaglutide use is plausible and supported by prescribing trend data internationally.

Type 2 diabetes in children and adolescents has been rising in Australia, tracking closely with increases in pediatric obesity. A 2022 paper by Constantino et al. in The Medical Journal of Australia documented accelerating rates of youth-onset type 2 diabetes, particularly in Indigenous communities. Treating both glycemic control and weight simultaneously is not fringe medicine. The American Diabetes Association's 2024 Standards of Care explicitly supports GLP-1 receptor agonist use in adolescents aged 10 and over with type 2 diabetes, citing the landmark ELLIPSE trial (Tamborlane et al., 2019, NEJM) which demonstrated liraglutide's efficacy and safety in this group. Semaglutide data in adolescents is newer but growing, including the STEP TEENS trial (Weghuber et al., 2022, NEJM), which showed significant weight reduction in adolescents with obesity, though that population did not require a diabetes diagnosis.

So the science does support GLP-1 use in pediatric type 2 diabetes. The segment's alarmist framing oversimplifies a legitimate clinical conversation.

What did they get wrong (or right)?

They got the lifestyle piece right. The doctor's insistence that medication must be used "in conjunction with lifestyle advice" including nutrition, activity, sleep, and screen time reflects genuine clinical consensus. That is not a throwaway disclaimer. Evidence from the TODAY2 study (TODAY Study Group, 2021, NEJM) shows that pediatric type 2 diabetes progresses faster than adult-onset disease, making multimodal treatment genuinely necessary, not optional.

What they got wrong, or at least muddled, is the framing of semaglutide use as inherently concerning in children with diabetes. Calling it a "surge" without publishing the actual TGA numbers makes the claim unverifiable. The word "injecting" is used in a way that carries implicit risk connotations, even though subcutaneous injection is standard for this drug class. The segment also does not distinguish between on-label prescribing by a physician for diabetes versus unsupervised or cosmetic use, and that distinction is the entire story here.

• The "divided medical community" claim is vague. On GLP-1 use for pediatric type 2 diabetes specifically, the evidence base is actually building toward consensus, not division.
• The weight loss hashtags in the caption misrepresent the clinical framing of the segment itself.

What should you actually know?

If your child or a child you care for has been diagnosed with type 2 diabetes, the conversation about GLP-1 receptor agonists belongs with a pediatric endocrinologist, not a TikTok comment section. Here is what the current evidence actually supports.

Liraglutide (Victoza) has the strongest pediatric safety and efficacy data for type 2 diabetes in adolescents from age 10. Semaglutide's pediatric data is emerging and promising but less extensive. Neither drug is approved by the TGA or any major regulator for general weight loss in children without a medical indication. The doctor in this segment is correct that lifestyle intervention is not optional, it is foundational. GLP-1 drugs work better alongside behavioral change, not instead of it.

• Prescribing trends rising in children does not automatically mean over-prescribing. It may reflect better diagnosis and more treatment options.
• The TGA monitors pediatric prescribing data, and any parent with concerns about their child's treatment should speak directly with their treating clinician or seek a second opinion from a pediatric specialist.
• Compounded semaglutide products are not equivalent to TGA-approved formulations and should never be used in children under any circumstances.